Metraipolis › archive › dc_d196ca028f9a

Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges — Europe PMC PMID:41409165

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41409165
DOI
10.1021/acsptsci.5c00521
License (as archived)
solo-consultazione
Archived
2026-11-08T11:47:31.362Z
SHA-256 of the archived text
adf98a5ef3f6f39fb5310197eb7b3f16e550229673be5e738388beb8ee1eab53
Stable URL of this page
https://metraipolis.com/documento/dc_d196ca028f9a

How to cite

Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges — Europe PMC PMID:41409165 — Europe PMC (en), https://europepmc.org/article/MED/41409165 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d196ca028f9a (Metraipolis archive dc_d196ca028f9a, sha256 adf98a5ef3f6f39fb5310197eb7b3f16e550229673be5e738388beb8ee1eab53)
BibTeX
@misc{dcd196ca028f9a,
  title = {Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges — Europe PMC PMID:41409165},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41409165},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d196ca028f9a; sha256 adf98a5ef3f6f39fb5310197eb7b3f16e550229673be5e738388beb8ee1eab53},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41409165. Agents can read the archived copy with the MCP tool read_document.